Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Cipla
Novartis
Teva
Boehringer Ingelheim
Healthtrust
Chinese Patent Office
Fuji
Moodys
Julphar

Generated: January 16, 2018

DrugPatentWatch Database Preview

Pierre Fabre Company Profile

« Back to Dashboard

Summary for Pierre Fabre
International Patents:38
US Patents:1
Tradenames:3
Ingredients:3
NDAs:3

Drugs and US Patents for Pierre Fabre

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pierre Fabre NAVELBINE vinorelbine tartrate INJECTABLE;INJECTION 020388-001 Dec 23, 1994 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pierre Fabre ETOPOSIDE etoposide INJECTABLE;INJECTION 074813-001 Jul 9, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Pierre Fabre

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,987,262 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas ➤ Subscribe
9,173,858 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Pierre Fabre Drugs

Supplementary Protection Certificates for Pierre Fabre Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0035 Belgium ➤ Subscribe PRODUCT NAME: ETOPOSIDE PHOSPHATE; NAT. REGISTRATION NO/DATE: NL 21192 19960520; FIRST REGISTRATION: SE - 12512 19960412
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Dow
Fuji
Citi
Baxter
US Department of Justice
Mallinckrodt
Boehringer Ingelheim
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot